why choose us

First received: February 20, 2023

Clinical Trial: Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Study Status: Completed

Recruit Status: RECRUITING

Condition: Bladder Squamous Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Brief Summary: This phase II trial tests how well enfortumab vedotin (EV) and pembrolizumab works in treating patients with bladder cancer of variant histology (a group of less common types of bladder cancer) that have spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic).Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin.Enfortumab attaches to a protein called nectin-4 on…

Read more